Adaptive Biotechnologies (ADPT) Tops Q3 EPS by 2c; Reports Cash and Cash Equivalents of $632.4M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to Adaptive Biotechnologies (ADPT) Tops Q3 EPS by 2c; Reports Cash and Cash Equivalents of $632.4M

Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results

November 3, 2021 4:05 PM EDT

SEATTLE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2021.

We are pleased to deliver another quarter of strong growth with continued momentum across research, diagnostic and drug discovery, said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. Achievements during the quarter mark important advancements in the evolution of our immune medicine platform as a clinical product development engine.

... More